Episodebeskrivelse
Billions are flowing into longevity and biotech, but how do investors tell a genuine breakthrough from an expensive scientific dead end? Sergey Jakimov, founding and managing partner of LongeVC, joins Daphna Stern on Beyond Longevity to explain how investors decide which companies deserve backing. He says his team has reviewed almost 5,000 companies since 2021 and invested in only a tiny fraction.
Sergey shares the problems he sees again and again: overstated science, weak intellectual property and no credible route through clinical trials and regulatory approval. He also explains why some…
Nettsted: beyond-longevity.co.uk

